Systemic sclerosis disease modification clinical trials design: quo vadis? - Wikidata - awgldk - TriplyDB

Systemic sclerosis disease modification clinical trials design: quo vadis?

Systemic sclerosis disease modification clinical trials design: quo vadis?

http://www.wikidata.org/entity/Q36067226

about

Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Rituximab in early systemic sclerosis.

P2860

Q37381549-F126D4FC-AA07-4692-9067-CF2373C277E9 Q41544232-5A931B2A-09B5-4C86-A041-EE60B93F8355

P2860

Systemic sclerosis disease modification clinical trials design: quo vadis?

http://www.wikidata.org/entity/Q36067226

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Systemic sclerosis disease modification clinical trials design: quo vadis?

@ast

Systemic sclerosis disease modification clinical trials design: quo vadis?

@en

type

label

Systemic sclerosis disease modification clinical trials design: quo vadis?

@ast

Systemic sclerosis disease modification clinical trials design: quo vadis?

@en

prefLabel

Systemic sclerosis disease modification clinical trials design: quo vadis?

@ast

Systemic sclerosis disease modification clinical trials design: quo vadis?

@en

P1433

Q36067226-D144A9AF-D916-4906-9D9E-A813DA2E386A

P1476

Q36067226-9B4CE273-99BE-46A4-8C0A-659F898E1ABC

P2093

Q36067226-21BC55FA-685F-404B-BC32-E53920422AC5

Q36067226-382F901F-4377-44BF-ACBC-4A38DE5A79F2

Q36067226-B031E0D0-F184-4410-A561-1AAE0547C83E

P2860

Q36067226-006DBD11-5D35-477C-ACBF-257808968079

Q36067226-0A44FA38-FCBB-466D-BF85-08C907613A1D

Q36067226-1554C34C-02F4-4A38-8072-D8D932CC7482

Q36067226-17E972CF-F822-4B3B-9CCF-CD98CDAD0119

Q36067226-18272789-B76E-4886-936C-7F5B1EA9A458

Q36067226-34E0C12D-5F47-440C-8D16-7740E1D43901

Q36067226-375643D1-2E74-48B1-AD36-4B8D3FCBE6E5

Q36067226-3D8284DA-96FC-41AA-9BE1-EADC60413E8D

Q36067226-43BA6C9E-0489-46E8-B150-1B5ACB3205C3

Q36067226-45B381A8-13A1-46A2-822D-1378A4BB94C8

P304

Q36067226-7F644D95-02DE-4F7F-9F78-E97017829008

P31

Q36067226-13348A20-6307-4FB4-BDD4-C3EF4918FF76

P356

Q36067226-266EAD40-D8A8-4A57-A3DE-B435D9000331

P433

Q36067226-E1DC8684-7AA4-43E1-BA15-9C67AE3FF1CB

P478

Q36067226-AB2D5D5D-0A39-4D0D-8E3A-B014A923E017

P577

Q36067226-294B2B73-1543-4FD2-9BD3-FF0C45703204

P5875

Q36067226-F556969B-BCB5-4AA2-B833-CF2B2DF9DE8E

P698

Q36067226-FCDE5E48-EC53-4DE5-9DFC-77E086023FD2

P932

Q36067226-74D7381B-418A-4B5A-A403-2D15380CC1BC

P356

P1433

Arthritis Care and Research

P1476

Systemic sclerosis disease modification clinical trials design: quo vadis?

@en

P2093

Fabian A Mendoza

http://www.w3.org/2001/XMLSchema#string

Lynette L Keyes-Elstein

http://www.w3.org/2001/XMLSchema#string

Sergio A Jimenez

http://www.w3.org/2001/XMLSchema#string

P2860

Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression

Molecular subsets in the gene expression signatures of scleroderma skin.

Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?

Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Cyclophosphamide versus placebo in scleroderma lung disease.

Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.

Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design

P304

945-954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.21667

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221709375

http://www.w3.org/2001/XMLSchema#string

P698

22422541

http://www.w3.org/2001/XMLSchema#string

P932

3386473

http://www.w3.org/2001/XMLSchema#string